Roche’s oral GLP-1 receptor agonist CT-996 has weight loss of -6.1% within four weeks
Roche has reported positive topline results from two arms of an ongoing multi-part Phase I clinical trial for CT-996, an investigational,...
top of page
Browse by category
Search
Roche enters weight loss and metabolic market with Carmot Therapeutics acquisition
Roche has completed its acquisition of Carmot Therapeutics, which includes Carmot’s R&D portfolio including all clinical and pre-clinical...
Roche poised to enter anti-obesity medication market with agreement to acquire Carmot Therapeutics
Roche is poised to enter the lucrative anti-obesity medication market after entering into a definitive merger agreement to acquire Carmot...
Browse by tag
bottom of page